Results 71 to 80 of about 73,544 (253)

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Engineered 3D cultured human nasal mucosa mesenchymal stem cell derived sEVs for targeted brain‐derived neurotrophic factor delivery to enhance neurogenesis and attenuate brain damage

Interdisciplinary Medicine, EarlyView.
This study successfully developed and evaluated BDNF@RVG‐sEVs, a novel brain‐targeted nanomedicine based on hnmMSC‐derived sEVs, designed to overcome the BBB and enhance neurorestoration. By integrating RVG for enhanced brain targeting and encapsulating BDNF for potent neurorepair, our system address the key limitations of the conventional sEVs and ...
Xueting Wang, Junge Chen, Jiao Xia, Weitong Yang, Teng Ma, Tianzi Shan, Weifeng He, Gaoman Zhang, Zhuoran Xia, Weiwei Wang, Zhusheng Liu, Zhiqiang Yi, Piye Niu, Tian Chen   +13 more
wiley   +1 more source

Isolating transdiagnostic effects reveals specific genetic profiles in psychiatric disorders

JCPP Advances, EarlyView.
Abstract Background Evidence indicates substantial genetic overlap between psychiatric diagnoses. Accounting for these transdiagnostic effects can sharpen research on disorder‐specific genetic architecture and patterns of comorbidity. Methods We applied genomic structural equation modeling to genome‐wide association study summary statistics from 11 ...
Engin Keser, Wangjingyi Liao, Andrea G. Allegrini, Kaili Rimfeld, Thalia C. Eley, Robert Plomin, Margherita Malanchini   +6 more
wiley   +1 more source

Restricted effects of androgens on glucocorticoid signaling in the mouse prefrontal cortex and midbrain

Frontiers in Endocrinology
Glucocorticoids are key executors of the physiological response to stress. Previous studies in mice showed that the androgen receptor (AR) influenced the transcriptional outcome of glucocorticoid treatment in white and brown adipocytes and in the liver ...
Jorge Miguel Amaya, Jorge Miguel Amaya, Hetty C. M. Sips, Hetty C. M. Sips, Eva M. G. Viho, Eva M. G. Viho, Jan Kroon, Jan Kroon, Onno C. Meijer, Onno C. Meijer   +9 more
doaj   +1 more source

The subcortical cocktail problem; mixed signals from the subthalamic nucleus and substantia nigra.

PLoS ONE, 2015
The subthalamic nucleus and the directly adjacent substantia nigra are small and important structures in the basal ganglia. Functional magnetic resonance imaging studies have shown that the subthalamic nucleus and substantia nigra are selectively ...
Gilles de Hollander, Max C Keuken, Birte U Forstmann   +2 more
doaj   +1 more source

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo

Brain Stimulation
Background: Deep brain stimulation (DBS) has been widely used to manage debilitating neurological symptoms in movement disorders such as Parkinson's disease (PD).
Eun Jung Lee, David Hernán Aguirre-Padilla, Anton Fomenko, Grishma Pawar, Minesh Kapadia, Jimmy George, Andres M. Lozano, Clement Hamani, Lorraine V. Kalia, Suneil K. Kalia   +9 more
doaj   +1 more source

Placebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.
Luiz Vinicius Silva Correa, Alexandre Martins do Nascimento, Bruno Lopes Santos‐Lobato, Henry Mauricio Chaparro‐Solano, Ignacio Fernandez Mata, Vitor Tumas   +5 more
wiley   +1 more source

Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson’s disease: A DNA co-methylation network analysis

npj Parkinson's Disease
Parkinson’s disease is a highly heterogeneous disorder, encompassing a complex spectrum of clinical presentation including motor, sleep, cognitive and neuropsychiatric symptoms.
Joshua Harvey, Adam R. Smith, Luke S. Weymouth, Rebecca G. Smith, Isabel Castanho, Leon Hubbard, Byron Creese, Catherine Bresner, Nigel Williams, Ehsan Pishva, Katie Lunnon   +10 more
doaj   +1 more source

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source